MIVOLIS Sweetener Tablets 2400 pcs. - Table Sweeteners | Germany

Product Information

All NSAIDs, both COX-2 selective and nonselective, may cause an increased risk of serious cardiovascular thrombotic events. This may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. tumefactie brusca a pielii sau a mucoasei, cum ar fi tumefactii la nivelul ochilor, fetei, buzelor, gurii sau pieptului, care pot sa determine dificultati in respiratie (edem angioneurotic) Lactose monohydrate. Movalis tablets 7.5 mg contain 47 mg lactose monohydrate and Movalis tablets 15 mg contain 20 mg lactose monohydrate per maximum recommended daily dose. Patients with rare hereditary conditions of galactose intolerance, e.g. galactosaemia, should not take this medicine.

Renal effects. NSAIDs inhibit the synthesis of renal prostaglandins, which play a supportive role in the maintenance of renal perfusion. In patients whose renal blood flow and blood volume are decreased, administration of an NSAID may precipitate overt renal decompensation which is typically followed by recovery to pretreatment state upon discontinuation of nonsteroidal anti-inflammatory therapy.Renal impairment. Meloxicam pharmacokinetics have been investigated in subjects with different degrees of renal insufficiency. Total drug plasma concentrations decreased with the degree of renal impairment, while free AUC values were similar. Total clearance of meloxicam increased in these patients, probably due to the increase in free fraction, leading to an increased metabolic clearance. There is no need for dose adjustment in patients with mild to moderate renal failure (creatinine clearance greater than 25 mL/min). Patients with severe renal insufficiency have not been adequately studied. The use of Movalis in patients with severe renal impairment is not recommended. Movalis should be used at the lowest dose and for the shortest duration consistent with effective treatment. Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs. Movalis Hypertension interaction Studies in rats with meloxicam, as with other drugs known to inhibit prostaglandin synthesis, showed an increased incidence of still births, increased length of delivery time and delayed parturition at oral doses ≥ 1 mg/kg/day (approximately 0.6 times the human dose based on BSA), and decreased pup survival at an oral dose of 4 mg/kg/day (approximately 2.1 times the human dose based on BSA) throughout organogenesis. Similar findings were observed in rats receiving oral doses ≥ 0.125 mg/kg/day (less than 0.1 times the human dose based on BSA) during late gestation and the lactation period. terfenadine and astemizole, medicines used to prevent or relieve the symptoms of allergy, such as hay fever or insect stings

MOVALIS may hide some of the signs of an infection (eg. pain, fever, redness and swelling). You may think, mistakenly, that you are better or that the infection is not serious. Things you must not do Movalis este un antiinflamator indicat pentru tratamentul simptomatic al artritei reumatoide, tratamentul simptomatic al osteoartritelor dureroase ( artroze, boli degenerative ale articulatiilor); alte stari inflamatorii. Movalis este un ains din clasa acizilor enolici, cu proprietati antiinflamatoare, analgezice si antipiretice. Mecanismul, comun pentru toate efectele, se datoreaza capacitatii Movalis de a inhiba biosinteza prostaglandinelor, cunoscuti mediatori ai inflamatiei. In vivo, Movalis inhiba mai mult biosinteza prostaglandinelor de la locul inflamatiei, decat a celor din mucoasa gastrica sau din rinichi. Acest grad crescut de protectie se datoreaza inhibarii selective a COX 2, fata de COX 1. Dovezile existente arata ca inhibarea COX 2 intretine efectele terapeutice ale AINS, pe cand inhibarea COX 1 este responsabila de efectele secundare gastrointestinale si renale. Studiile clinice au demonstrat o incidenta scazuta a efectelor secundare gastrointestinale (inclusiv a perforatiilor, ulceratiilor si sangerarilor) la dozele recomandate de meloxicam, decat la cele ale antiinflamatoarelor standard. The use of Movalis tablets is contraindicated in patients with rare hereditary galactose intolerance, due to the lactose content of the formulations. Use in patients with fever and infection. The pharmacological activity of Movalis in reducing inflammation and possibly fever may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.

Precaution

Metotrexat: AINS pot reduce excreţia tubulară a metotrexatului crescând astfel concentraţiile plasmatice de metotrexat. Din această cauză, nu se recomandă administrarea concomitentă de AINS la pacienţi care iau doze mari de metotrexat (mai mult de 15 mg/săptămână). Riscul unei interacţiuni dintre medicamentele din grupul AINS şi metotrexat, trebuie avut în vedere şi la pacienţii care primesc doze mici de metotrexat, în special la cei cu funcţia renală afectată. Dacă este necesară această asociere, se vor monitoriza hemograma/ formula sanguină şi funcţia renală. Se recomandă prudenţă în cazul în care se administrează şi AIDS şi metotrexat în decurs de 3 zile, deoarece în acest caz valorile plasmatice de metotrexat pot creşte şi pot să mărească toxicitate. Deşi proprietăţile farmacocinetice ale metotrexatului (15 mg/săptămână) nu au fost afectate în mod relevant prin administrarea concomitentă de meloxicam, se va lua în considerare faptul că toxicitatea sanguină a metotrexatului poate fi amplificată de tratamentul cu AINS. Cimetidine. Concomitant administration of 200 mg cimetidine QID did not alter the single dose pharmacokinetics of 30 mg meloxicam.